echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > First-line treatment of gastroesophageal adenocarcinoma HER2 targeting bispecific antibody achieves 90.9% disease control rate

    First-line treatment of gastroesophageal adenocarcinoma HER2 targeting bispecific antibody achieves 90.9% disease control rate

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Zymeworks announced that it is investigating zanidatamab, a bispecific antibody therapy targeting HER2, and has achieved positive results in a first-line clinical trial for the treatment of HER2-expressing gastroesophageal adenocarcinoma (GEA) patients
    .
    As of March 18, 2021, of the 22 patients that can be evaluated, zanidatamab was used in combination with standard chemotherapy to achieve a confirmed objective response rate of 68.
    2%

    .
    The latest results of this experiment will be announced at the ESMO conference on September 16

    .

    Zanidatamab is a bispecific antibody that can simultaneously bind to two non-overlapping epitopes of HER2
    .
    This unique design produces multiple mechanisms of action, including dual HER2 signal blockade, increased clearance of HER2 protein from the cell surface, and enhanced antibody-mediated cytotoxicity, resulting in encouraging anti-tumor activity in patients

    .
    BeiGene has reached a research and development cooperation agreement with Zymeworks, and has obtained the exclusive authorization for the development and promotion of zanidatamab in Asia (except Japan), Australia and New Zealand

    .
    The application for clinical trials of this innovative treatment in China has also passed "implicit permission

    .
    "

    ▲Zanidatamab has a unique mechanism of action (picture source: reference [2])

    Reference materials:

    [1] Zymeworks Announces Abstract for Zanidatamab in First-line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual Congress.
    Retrieved September 12, 2021, from https:// news/home/20210912005060/en

    [2] Zymeworks Corporate Presentation.
    Retrieved December 5, 2020, from https://s23.
    q4cdn.
    com/709109388/files/doc_presentations/2020/11/Zymeworks_Corporate-Presentation.
    pdf

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.